COPENHAGEN, Denmark, September 13 /PRNewswire/ --

- Summary: Genmab Announces the Initiation of a Phase III Study of
HuMax-EGFr to Treat Head and Neck Cancer in Cooperation With DAHANCA.

Genmab A/S (OMX: GEN) announced today the initiation of a Phase III study
of HuMax-EGFr(TM) (zalutumumab) to treat head and neck cancer in cooperation
with the Danish Head and Neck Cancer Group (DAHANCA). The study will include
approximately 600 previously untreated head and neck cancer patients to
assess whether concomitant therapy with HuMax-EGFr can improve the efficacy
of primary curative radiotherapy.

"We are excited for DAHANCA to begin the largest HuMax-EGFr trial to
date," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We
hope that HuMax-EGFr provides additional benefit to head and neck cancer
patients receiving radiotherapy."

About the trial Patients in the study will be randomized to treatment
with radiotherapy or HuMax-EGFr plus radiotherapy. All patients will receive
treatment with accelerated radiotherapy plus nimorazole and may also receive
cisplatin chemotherapy. Patients receiving HuMax-EGFr will receive six weekly
doses of 8 mg/kg of HuMax-EGFr. Patients will be followed for at least 5
years and will be clinically evaluated at months 2, 5, 8 and 12 after
completion of treatment. Evaluations will continue every 4 months in the
second year and every 6 months the third and fourth year and once a year
thereafter.

The objective of the study is to determine the efficacy of HuMax-EGFr in
combination with radiotherapy in treating patients with squamous cell
carcinoma of the head and neck. The primary endpoint is loco-regional control
and secondary endpoints are overall survival, disease free survival and acute
and late side effects.

About cancers of the head and neck Head and neck cancers may affect the
mouth, nasal cavities, sinuses, larynx and pharynx. Most are squamous
carcinomas but others include lymphoepithelioma and lymphoma. Head and neck
cancers account for 3 % of all cancers in the U.S., with 40,000-60,000 cases
diagnosed and 12,000 deaths annually. Worldwide incidence is about half a
million with nearly 250,000 deaths.

About Genmab A/S Genmab is a leading international biotechnology company
focused on developing fully human antibody therapeutics for unmet medical
needs. Using unique, cutting-edge antibody technology, Genmab's world class
discovery and development teams have created and developed an extensive
pipeline of products for potential treatment of a variety of diseases
including cancer and autoimmune disorders. As Genmab advances towards a
commercial future, we remain committed to our primary goal of improving the
lives of patients who are in urgent need of new treatment options. For more
information on Genmab's products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM);
HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all
trademarks of Genmab A/S.

Stock Exchange Release no. 38/2007